Latest News & Features
Asia
The China National Intellectual Property Administration has accepted its first set of drug patent linkage complaints since the introduction of a new patent law in June 2021. 9 November 2021
Medtech
Qiagen will pay Becton, Dickinson $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction diagnostics patents. 9 November 2021
Big Pharma
Novartis yesterday, November 4, announced that it is selling its entire stake in Roche—equating to 53.3 million bearer shares—back to the Swiss healthcare company for the sum of $20.7 billion. 5 November 2021
article
The 1999 Japanese Supreme Court judgment in the case of Ono Pharmaceuticals Co Ltd vs Kyoto Pharmaceutical Industries Ltd, held that carrying out necessary experiments to apply for approval of generic drugs stipulated in article 14 of the Pharmaceutical Affairs Act falls within “working of the patented invention for experiment or research”, however the original drugs are not mentioned. 4 November 2021
Americas
Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark. 4 November 2021
Generics
Following two-day oral proceedings at the Munich Board of Appeal of the European Patent Office, the court has upheld the validity of a Bayer Pharmaceuticals’ dosing patent for Xarelto. 4 November 2021
Medtech
The US Court of Appeals for the Federal Circuit has ruled that yet another CardioNet heart monitor patent is invalid for not citing an inventive concept under the Alice test. 2 November 2021
Americas
Medical device company Nevro has been hit with a $20m damages verdict after a US jury found that it had infringed two patents owned by Boston Scientific. 2 November 2021
Big Pharma
Mylan has failed to secure a stay in litigation centring on a melatonin-based insomnia patent at the English High Court. 2 November 2021
Big Pharma
UN-backed public health organisation The Medicine Patent Pool (MPP) has entered into a licence agreement with Merck Sharp & Dohme (MSD) and others to increase access to molnupiravir (MK-4482, EIDD-2801)—an investigational oral COVID-19 medicine—for low-and-middle-income countries (LMIC). 28 October 2021